FIGURE 9.

C11 treatment alters Tau polymerization in a cellular, Tau aggregation assay system. A, GFP-Tau-transfected human embryonic kidney cells were incubated in culture for 24 h. Cells were then incubated with either DMSO vehicle (■) or 1 μm C11 (□) for a further 2 days. Fluorescence in control cells decreased 50 ± 0.97% during incubation (from 35,993.8 fluorescence units to 18,011.8). However, drug treatment resulted in a 62 ± 1.27% decrease in fluorescence (from 32,696.4 to 12,326.1 units), indicating that 1 μm C11 significantly increased Tau polymerization. B, cells were allowed to incubate in culture for 2 days prior to treatment to accumulate polymerized Tau. Following this, cells were treated with either DMSO vehicle (■) or 0.01 μm C11 (□). Fluorescence in vehicle-treated cells decreased 22 ± 2.78% from 34,854 to 27,237. In contrast, treated cells demonstrated no significant loss of signal (35,436 to 33,835).